Insmed (INSM) did not whisper a beat. It rewrote the year.
Second-quarter revenue hit about $425.5 million. The drug everyone is watching, BRINSUPRI, printed roughly $309.2 million, up about 49% sequentially. The stock ripped on the order of 30% as traders priced a real commercial franchise, not a science project.
Then management did the thing biotech bulls wait years to hear. Full-year 2026 BRINSUPRI guidance moved to $1.25 billion to $1.40 billion, up from the prior "at least $1 billion" floor. ARIKAYCE stayed at $450 million to $470 million.
Why the Raise Mattered More Than the Beat
Plenty of biotechs can print one hot quarter. Raising the full-year floor says the launch is still adding patients, not just front-loading the early adopters. Management pointed to roughly 7,000 new patient starts in the quarter and more than 6,300 cumulative prescribers. That is boots-on-the-ground demand language, not slide-deck poetry.
They also lifted peak sales talk for the lead programs. BRINSUPRI peak estimates moved above $7 billion. Combined peak talk across the lead franchise stack now sits above $14 billion. You do not have to buy the peak number at face value. You do have to admit the Street just got permission to model a bigger company.
What Can Still Go Wrong
This is still a high-expectation name. Gross-to-net, payer friction, and competition can all clip a launch after the first fireworks. A 30% one-day move also means a lot of the good news is already in the price by Friday's open. If the next update is merely "fine," the stock can give back a chunk without the fundamental story dying.
For now, the clean read is simple. Insmed turned a chronic-lung launch into a growth engine fast enough that management had to raise the bar in public.
Bottom Line
Bottom Line: INSM's day was about commercial proof, not a cute EPS beat. The open loop is whether BRINSUPRI can keep compounding patient starts into the back half without the Street moving the goalposts again.
Comments
Log in or sign up to join the conversation.